A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029) | MicrobiomeTrials
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
RecruitingPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2025-08-21Est. Completion: 2033-12-04
Enrollment target: 153 participants
Locations
Nemours/Alfred I. duPont Hospital for Children ( Site 0001), Wilmington, Delaware, United States
Children's National Medical Center ( Site 0015), Washington D.C., District of Columbia, United States
Excel Medical Clinical Trials ( Site 0008), Boca Raton, Florida, United States
Children's Healthcare of Atlanta Cardiology ( Site 0026), Atlanta, Georgia, United States
Boston Children's Hospital ( Site 0018), Boston, Massachusetts, United States
St. Louis Children's Hospital ( Site 0014), St Louis, Missouri, United States
Cincinnati Children's Hospital Medical Center ( Site 0016), Cincinnati, Ohio, United States
West Virginia University ( Site 0013), Morgantown, West Virginia, United States
Monash Children s Hospital ( Site 1603), Clayton, Victoria, Australia
Perth Children s Hospital ( Site 1601), Nedlands, Western Australia, Australia
UZ Antwerpen ( Site 0601), Edegem, Antwerpen, Belgium
Universidade Federal Do Ceara ( Site 0201), Fortaleza, Ceará, Brazil
Instituto Dante Pazzanese de Cardiology ( Site 0206), São Paulo, Brazil
Incor - Instituto do Coracao ( Site 0200), São Paulo, Brazil
Other microbiome trials you might be interested in